{"database": "openregs", "table": "documents", "rows": [["FDA-2015-N-1260-0002", "FDA", "FDA-2015-N-1260", "Reference 5 Letter to K. Irwin, President and CEO, Omni Neutraceuticals, Inc., from D. Horowitz, Acting Director, Office of Compliance, CDER, re \u2018\u2018Inholtra Joint Pain Caplets and Inholtra Joint Pain Plus\u2019\u2019 (October 16, 2001).", "Supporting & Related Material", "Background Material", "2015-12-23T05:00:00Z", 2015, 12, null, null, "2015-12-23T21:57:20Z", null, 0, 0, "0900006481dcf789"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2015-N-1260-0002"], "units": {}, "query_ms": 16.840392956510186, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}